Insight

Sevinç Balli: Low dose Nivolumab maybe an option?

Sevinç Balli/researchgate.net

Apr 4, 2025, 17:22

Sevinç Balli: Low dose Nivolumab maybe an option?

Sevinç Balli, Medical Oncologist at Ankara University, shared JCO Global Oncology’s post on X:

“Low dose Nivolumab maybe an option?”

Quoting JCO Global Oncology’s post on X about a recent paper by Praveen Kumar Marimuthu et al. published in ASCO Publications:

“Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched Analysis”

Authors: Praveen Kumar Marimuthu et al.

Sevinç Balli

Ajoy Oommen John and Ashish Singh. Anjana Joel Aparna Irodi Balamugesh Thangakunam Balukrishna Sasidharan Barney T.J. Isaac cancer Deepa Susan Joy Philip Divya Bala Thumaty Jansi Rani JCO Global Oncology Josh Thomas Georgy Kovilapu Harikrishna Lung cancer Manu Mathew NSCLC OncoDaily Oncology Prashant Jambunathan Praveen Kumar Marimuthu Rajesh Isiah Raju Titus Chacko Richa Gupta Sevinc Balli Simon Pradeep Pavamani Thomas Alex Kodiatte Zachariah Thomas

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Clifford Hudis and Thomas Kurian Discussed AI in Oncology and ASCO Guidelines Assistant at ASCO 2025

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL